… -kinase inhibitor erlotinib has … the phase 3, placebo-controlled Sequential Tarceva in
Unresectable NSCLC (SATURN; BO18192) study to assess use of erlotinib as maintenance therapy …

… agent erlotinib as maintenance therapy is an active treatment after cCRT in patients with stage
III NSCLC, … The safety profile of maintenance erlotinib was as expected and manageable. …

… erlotinib has shown to be an effective maintenance treatment [6]. In mCRC, this maintenance
strategy was tested in a phase II trial [7]… The present phase III trial was designed to compare …

… Background: Erlotinib (E), a small-molecule EGFR TKI, is proven to extend survival versus
… The phase III SATURN study (BO18192) was initiated to evaluate E as maintenance therapy …

… , placebo-controlled phase III trial of maintenance erlotinib versus erlotinib at the time of …
benefit observed in this trial, the use of maintenance treatment with erlotinib in patients with …

… ; BO18192) study of erlotinib as maintenance treatment in … evaluated the efficacy and safety
of erlotinib in this setting. The … phase III SATURN study of erlotinib maintenance therapy, …

… Similar findings were reported in the phase III JMEN study of maintenance pemetrexed.
The HR for OS in patients with non-squamous NSCLC having SD after first-line chemotherapy …

… This phase III study investigated whether continuation maintenance with gemcitabine or
switch maintenance with erlotinib improves clinical outcome compared with observation in …

… the terms “erlotinib”, “bevacizumab”, “colorectal”, and “randomized”, and found one article
that reported on the same maintenance therapy regimen used in our study (Nordic ACT Trial). …

… If 50% of patients had EGFR + tumors by IHC (based on a phase III erlotinib trial in patients
with advanced NSCLC after failure of at least one prior chemotherapy regimen, wherein 47% …